Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Show all species
Show all synonyms
Select your species and application
anti-Rat (Rattus) Kallikrein 6 Antibodies:
anti-Mouse (Murine) Kallikrein 6 Antibodies:
anti-Human Kallikrein 6 Antibodies:
Go to our pre-filtered search.
Human Monoclonal Kallikrein 6 Primary Antibody for ELISA, WB - ABIN519338
Lou, Si, Chen, Sun, Zhang, Niu, Hu: Correlation between KLK6 expression and the clinicopathological features of glioma. in Contemporary oncology (Pozna?, Poland) 2014
Mouse (Murine) Polyclonal Kallikrein 6 Primary Antibody for ELISA, WB - ABIN4328114
Iwata, Maruyama, Akagi, Hashikawa, Kanazawa, Tsuji, Nukina: Alpha-synuclein degradation by serine protease neurosin: implication for pathogenesis of synucleinopathies. in Human molecular genetics 2003
Data show that kallikrein 6 (KLK6 (show KLK1 Antibodies)) expression is induced in mouse and human skin during chronic glucocorticoid treatment.
Klk6 (show KLK1 Antibodies) represents an important target for conditions in which pro-inflammatory responses play a critical role in disease development, including MS
KLK6 (show KLK1 Antibodies) protein from 129 mice showed reduced SDS (show SDS Antibodies)-PAGE mobility compared with that from C57BL/6 mice; recombinant KLK6 (show KLK1 Antibodies) protein from 129 mice had a higher optimum pH and >15 times higher hydrolytic enzymatic activity for several substrates than that from C57BL/6 mice. These results suggest that KLKs may contribute to the genetic basis of the differences between mouse strains.
these data point to a novel kallikrein 6 (show KLK1 Antibodies) -signaling axis in neurons that is mediated by PAR1 (show F2R Antibodies) and PAR2 (show F2RL1 Antibodies) and is positioned to contribute to neurodegeneration
These results indicate that KLK6 (show KLK1 Antibodies) plays a functional role in oligodendrocyte development and the expression of myelin proteins.
Neuropathological analysis following delivery of LV-Neurosin to alpha-syn tg mice resulted in reduced accumulation of alpha-syn and reversal of neurodegenerative alterations in wild type but not A53T alpha-syn tg mice
We have found an increase in the level of neurosin, a key negative regulator of SNCA in the Ts65Dn mouse model for Down syndrome
KLK6 (show KLK1 Antibodies) is positioned to serve as a molecular trigger of select physiological processes involved in the development of astrogliosis
Klk8 is involved in the proliferation and migration of keratinocytes through Klk6 (show KLK1 Antibodies) in the early stages of wound healing, and possibly in keratinocyte differentiation associated with the upregulation of PAR2 (show F2RL1 Antibodies) in the late stages of wound healing.
neurosin plays a significant role in physiological alpha-synuclein degradation and also in the pathogenesis of synucleinopathies
Data show that kallikrein 6 (KLK6) expression is induced in mouse and human skin during chronic glucocorticoid treatment.
FST (show FST Antibodies) and KLK6 (show KLK1 Antibodies) may have significance in breast cancer detection
KLK6 (show KLK1 Antibodies) overexpression and likely its proteolytic activity is associated with alterations in downstream miRNAs and their targets, and these differ with the molecular subtypes of breast cancer.
Molecular models of peptides were built into the KLK6 (show KLK1 Antibodies) structure and the marked preference of the cut between the two R of the examined peptides was related to the extended conformation of the substrates
Our fine-mapping study has identified novel loci in the KLK6 (show KLK1 Antibodies) region strongly associated with aggressive PCa (show FLVCR1 Antibodies).
mRNA expression levels of KLK6 (show KLK1 Antibodies) and KLK8 (show KLK8 Antibodies) in advanced serous ovarian cancer
Data demonstrate that elevated levels of KLK6, KLK7 and KLK9 proteins are associated with poor glioblastoma patients survival.
Data indicate that elevated expression of microRNA-375 in head and neck squamous cell carcinoma (HNSCC) cells significantly reduces kallikrein 6 (KLK6), kallikrein 10 (KLK10 (show KLK10 Antibodies)), and matrix metalloproteinase 9 (MMP9 (show MMP9 Antibodies)) messenger RNA expression.
KLK6 (show KLK1 Antibodies) expression was detected in head and neck tumor cell lines (FaDu, Cal27 and SCC25), but not in HeLa cervix carcinoma cells.
KLK6 (show KLK1 Antibodies) and KLK7 (show KLK7 Antibodies) mRNA and protein overexpression is directly associated with early-stage ovarian tumors.
Kallikreins are a subgroup of serine proteases having diverse physiological functions. Growing evidence suggests that many kallikreins are implicated in carcinogenesis and some have potential as novel cancer and other disease biomarkers. This gene is one of the fifteen kallikrein subfamily members located in a cluster on chromosome 19. The encoded enzyme is regulated by steroid hormones. In tissue culture, the enzyme has been found to generate amyloidogenic fragments from the amyloid precursor protein, suggesting a potential for involvement in Alzheimer's disease. Multiple alternatively spliced transcript variants that encode different isoforms have been identified for this gene.
, P1 Kallikrein
, glandular kallikrein-8
, kallikrein 1-related peptidase b21
, prostatic glandular kallikrein-6
, serine protease
, tissue kallikrein
, brain serine protease
, kallikrein 29
, myelencephalon-specific protease
, myofibril-bound protease
, protease M
, protease, serine, 18
, protease, serine, 9
, kallikrein 6 (neurosin)
, kallikrein 6 (neurosin, zyme)
, protease serine 9 (neurosin)
, serine protease 18
, serine protease 9